The U.S. scar treatment market size is expected to reach $11.3 billion by 2023. The market is mainly driven by increasing number of surgeries for the improvement of physical appearance, growing prevalence of skin problems leading to scar formation, increasing expenditure on personal care, and technological advancements in dermatological products.

Request for report sample at: https://www.psmarketresearch.com/market-analysis/us-scar-treatment-market/report-sample

The increasing appearance consciousness among consumers due to exposure to media, is driving the demand for beauty products and cosmetic surgery.  The online availability of scar treatment products, such as scar treating creams, sprays, oils, gels leads to increased accessibility of these products. Also, online retailing is time saving, provides instant access to products, offers discounted prices, and is more convenient, which allows products to be purchased with ease.

The increasing prevalence of skin problems, due to excessive exposure to pollution and UV radiation, results in sunburns, reduced skin elasticity, and other skin diseases. These conditions, without proper treatment on time, can lead to the formation of scars. Various other skin problems, such as acne, burns, post-surgical marks and stretch marks, due to pregnancy or changes in body weight also lead to scar formation, which is boosting the demand of scar treatment products and therapies.

Browse full report at: https://www.psmarketresearch.com/market-analysis/us-scar-treatment-market

Furthermore, the technological advancements in scar treatment products and therapies help in the removal of scars easily. The availability of various products, such as creams, oils, gels, and sprays over the counter for treating scars leads to the growth of the U.S. scar treatment market.

Some of the other key players operating in the U.S. scar treatment market are Revitol Corporation Inc., CCA Industries Inc., Scarguard Labs LLC, Quantum Health, Valeant Pharmaceuticals International Inc., Pacific World Corporation, Merz Pharma GmbH & Co. KGaA, and Johnson & Johnson.

Source: P&S Intelligence